Top

Published in:

01-02-2019 | Original Article

Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress

Authors: Kaiyue Sun, Yuting Bai, Rong Zhao, Zijiao Guo, Xiang Su, Peiqi Li, Pengyu Yang

Published in: Metabolic Brain Disease | Issue 1/2019

Abstract

The present study was designed to evaluate the effects of matrine (MAT) on scopolamine (SCOP)-induced learning and memory impairment. After successive oral administration of MAT to mice for three days at doses of 0.4, 2, and 10 mg/kg, we assessed improvements in learning and memory and investigated the mechanism of action of SCOP-induced amnesia. Donepezil at a dose of 3 mg/kg was used as a standard memory enhancer. MAT significantly improved SCOP-induced learning and memory impairment in novel object recognition and Y-maze tests at doses of 0.4, 2, and 10 mg/kg. Furthermore, MAT inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and decreased oxidative stress in the brain, as evidenced by increased total antioxidant capacity, total superoxide dismutase levels, and catalase activities as well as decreased malondialdehyde levels. Additionally, there was a significant negative correlation between the percentage of spontaneous alternation in the Y maze and AChE activity in the cortex and hippocampus. MAT ameliorated SCOP-induced amnesia by the inhibition of both AChE/BuChE activities and oxidative stress. This study provides further evidence to encourage the development of MAT as a drug for the prevention or treatment of Alzheimer’s disease.

Alvarez-Jimenez R, Groeneveld GJ, van Gerven JM, Goulooze SC, Baakman AC, Hay JL, Stevens J (2016) Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. Br J Clin Pharmacol 82:1011–1021CrossRef

Alzheimer's Association (2016) 2016 Alzheimer's disease facts and figures. Alzheimers Dement 12:459–509CrossRef

Antunes M, Biala G (2012) The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 13:93–110

Araujo JA, Studzinski CM, Milgram NW (2005) Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging. Prog Neuro-Psychopharmacol Biol Psychiatry 29:411–422CrossRef

Banks WA (2012) Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev 64:629–639CrossRef

Bartus RT, Dean RL, Ljubic B, Lippa A (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–414CrossRef

Ben-Barak J, Dudai Y (1980) Scopolamine induces an increase in muscarinic receptor level in rat hippocampus. Brain Res 193:309–313CrossRef

Botton PH, Costa MS, Ardais AP, Mioranzza S, Souza DO, da Rocha JB, Porciúncula LO (2010) Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice. Behav Brain Res 214:254–259CrossRef

Chen JX, Shen HH, Niu M, Guo YM, Liu XQ, Han YZ, Zhang YM, Zhao YL, Bai BK, Zhou WJ, Xiao XH (2016) Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6. Virus Res 215:104–113CrossRef

Cui LL, Cai YJ, Cheng WW, Liu G, Zhao JG, Cao H, Tao H, Wang Y, Yin MK, Liu TT, Liu Y, Huang PR, Liu Z, Li KS, Zhao B (2017) A novel, multi-target natural drug candidate, Matrine, Improves Cognitive Deficits in Alzheimer's Disease Transgenic Mice by Inhibiting Aβ Aggregation and Blocking the RAGE/Aβ Axis. Mol Neurobiol 54:1939–1952CrossRef

Darvesh S (2013) Butyrylcholinesterase radioligands to image Alzheimer's disease brain. Chem Biol Interact 203:354–357CrossRef

Dighe SN, Deora GS, DelaMora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP (2016) Discovery and structure-activity relationships of a highly selective butyrylcholinesterase inhibitor by structure-based virtual screening. J Med Chem 59:7683–7689CrossRef

Espada S, Rojo AI, Salinas M, Cuadrado A (2009) The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neuro transmission with neuroprotection. J Neurochem 110:1107–1119CrossRef

Fodale V, Quattrone D, Trecroci C, Caminiti V, Santamaria LB (2006) Alzheimer's disease and anaesthesia: implications for the central cholinergic system. Br J Anaesth 97:445–452CrossRef

Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002) Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm (Vienna) 109:1053–1065CrossRef

Haider S, Batool Z, Ahmad S, Siddiqui RA, Haleem DJ (2018) Walnut supplementation reverses the scopolamine-induced memory impairment by restoration of cholinergic function via mitigating oxidative stress in rats: a potential therapeutic intervention for age related neurodegenerative disorders. Metab Brain Dis 33:39–51CrossRef

Hartmann J, Kiewert C, Duysen EG, Lockridge O, Greig NH, Klein J (2007) Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem 100:1421–1429CrossRef

Inestrosa NC, Dinamarca MC, Alvarez A (2008) Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. FEBS J 275:625–632CrossRef

Ladner CJ, Lee JM (1998) Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 57:719–731CrossRef

Li HJ, Li XJ, Bai ML, Suo YE, Zhang GH, Cao XY (2015) Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2. Int J Clin Exp Pathol 8:14793–14799PubMedPubMedCentral

Li J, Gao L, Sun K, Xiao D, Li W, Xiang L, Qi J (2016) Benzoate fraction from Gentiana rigescens Franch alleviates scopolamine-induced impaired memory in mice model in vivo. J Ethnopharmacol 193:107–116CrossRef

Liu X, Zhang X, Ma K, Zhang R, Hou P, Sun B, Yuan S, Wang Z, Liu Z (2016) Matrine alleviates early brain injury after experimental subarachnoid hemorrhage in rats: possible involvement of PI3K/Akt-mediated NF-κB inhibition and Keap1/Nrf2-dependent HO-1 induction. Cell Mol Biol (Noisy-le-grand) 62:38–44CrossRef

Liu W, Rabinovich A, Nash Y, Frenke D, WangY YMBH, Weinreb O (2017) Anti-inflammatory and protective effects of MT-031, a novel multitarget MAO-A and AChE/BuChE inhibitor in scopolamine mouse model and inflammatory cells. Neuropharmacology 113:445–456CrossRef

Lleó A, Greenberg SM, Growdon JH (2006) Current pharmacotherapy for Alzheimer's disease. Annu Rev Med 57:513–533CrossRef

López N, Tormo C, Blas ID, Llinares I, Alom J (2013) Oxidative stress in Alzheimer’s disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33:823–829CrossRef

Luque-Contreras D, Carvaja K, Toral-Rios D, Franco-Bocanegra D, Campos-Peña V (2014) Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer's disease? Oxidative Med Cell Longev 2014:497802CrossRef

Meng F, Wang J, Ding F, Xie Y, Zhang Y, Zhu J (2017) Neuroprotective effect of matrine on MPTP-induced Parkinson's disease and on Nrf2 expression. Oncol Lett 13:296–300CrossRef

Mesulam MM, Guillozet A, Shaw P, Levey A, Duysen EG, Lockridge O (2002a) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 110:627–639CrossRef

Mesulam M, Guillozet A, Shaw P, Quinn B (2002b) Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 9:88–93CrossRef

Milić M, Timić T, Joksimović S, Biawat P, Rallapalli S, Divljaković J, Radulović T, Cook JM, Savić MM (2013) PWZ-029, an inverse agonist selective for α₅ GABAA receptors, improves object recognition, but not water-maze memory in normal and scopolamine-treated rats. Behav Brain Res 241:206–213CrossRef

Naik RS, Hartmann J, Kiewert C, Duysen EG, Lockridge O, Klein J (2009) Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase deficient mice. J Pharm Pharm Sci 12:79–85CrossRef

Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4:273–277CrossRef

Qu Z, Zhang JZ, Yang HG, Gao J, Chen H, Liu CX, Gao WY (2017) Prunella vulgaris L, an edible and medicinal plant, attenuates scopolamine-induced memory impairment in rats. J Agric Food Chem 65:291–300CrossRef

Russ TC, Morling JR (2012) Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 9:CD009132

Sarter M, Bodewitz G, Stephens DN (1988) Attenuation of scopolamine-induced impairment of spontaneous alteration behaviour by antagonist but not inverse agonist and agonist beta-carbolines. Psychopharmacology 94:491–495CrossRef

Schroeter H, Williams RJ, Matin R, Iversen L, Rice-Evans CA (2000) Phenolic antioxidants attenuate neuronal cell death following uptake of oxidized low-density lipoprotein. Free Radic Biol Med 29:1222–1233CrossRef

Venkatesan R, Subedi L, Yeo EJ, Kim SY (2016) Lactucopicrin ameliorates oxidative stress mediated by scopolamine-induced neurotoxicitythroughactivationof the NRF2 pathway. Neurochem Int 99:133–146CrossRef

Xiao J, Li SY, Sui Y, Wu Q, Li XP, Xie BJ, Zhang MW, Sun ZD, Cui RJ (2014) Lactobacillus casei-01 facilitates the ameliorative effects of Proanthocyanidins extracted from Lotus seedpod on learning and memory impairment in scopolamine-induced amnesia mice. PLoS One 9:e112773CrossRef

Xu QQ, Xu YJ, Yang C, Tang Y, Li L, Cai HB, Hou BN, Chen HF, Wang Q, Shi XG, Zhang SJ (2016) Sodium Tanshinone IIA sulfonate attenuates scopolamine-induced cognitive dysfunctions via improving cholinergic system. Biomed Res Int 2016:9852536PubMedPubMedCentral

Yin LL, Zhu XZ (2005) The involvement of central cholinergic system in (+)-matrine-induced antinociception in mice. Pharmacol Biochem Behav 80:419–425CrossRef

Yue W, Li Y, Zhang T, Jiang M, Qian Y, Zhang M, Sheng N, Feng S, Tang K, Yu X, Shu Y, Yue C, Jing N (2015) ESC-derived basal forebrain cholinergic neurons ameliorate the cognitive symptoms associated with Alzheimer's disease in mouse models. Stem Cell Reports 5:776–790CrossRef

Zhao P, Zhou R, Zhu XY, Hao YJ, Li N, Wang J, Niu Y, Sun T, Li YX, Yu JQ (2015) Matrine attenuates focal cerebral ischemic injury by improving antioxidant activity and inhibiting apoptosis in mice. Int J Mol Med 36:633–644CrossRef

Title: Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress
Authors: Kaiyue Sun
Yuting Bai
Rong Zhao
Zijiao Guo
Xiang Su
Peiqi Li
Pengyu Yang
Publication date: 01-02-2019
Publisher: Springer US
Published in: Metabolic Brain Disease / Issue 1/2019
Print ISSN: 0885-7490
Electronic ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-018-0335-y

At a glance: The STEP trials

Springer Medicine

Neuroprotective effects of matrine on scopolamine-induced amnesia via inhibition of AChE/BuChE and oxidative stress

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Nicotinamide ribose ameliorates cognitive impairment of aged and Alzheimer’s disease model mice

Alkaline phosphatase: a potential biomarker for stroke and implications for treatment

Allicin attenuated chronic social defeat stress induced depressive-like behaviors through suppression of NLRP3 inflammasome

L-3-n-butylphthalide attenuates cognitive deficits in db/db diabetic mice

Establishment and evaluation of a model for predicting 3-month mortality in Chinese patients with hepatic encephalopathy

Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing